BioMotiv Revenue and Competitors
Estimated Revenue & Valuation
- BioMotiv's estimated annual revenue is currently $542.5k per year.
- BioMotiv received $63.0M in venture funding in August 2016.
- BioMotiv's estimated revenue per employee is $77,500
- BioMotiv's total funding is $166.8M.
Employee Data
- BioMotiv has 7 Employees.
- BioMotiv grew their employee count by 0% last year.
BioMotiv's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Legal Contracts Manager | Reveal Email/Phone |
2 | Project Leader | Reveal Email/Phone |
3 | Technical Operations Assistant | Reveal Email/Phone |
BioMotiv Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.8M | 5 | 0% | N/A | N/A |
#2 | $1.7M | 11 | 0% | N/A | N/A |
#3 | $0.8M | 5 | 0% | N/A | N/A |
#4 | $5.1M | 33 | 14% | N/A | N/A |
#5 | $64.6M | 417 | 2% | N/A | N/A |
#6 | $1.7M | 11 | -8% | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $7.4M | 48 | -41% | N/A | N/A |
#9 | $0.6M | 4 | 0% | N/A | N/A |
#10 | $0.9M | 12 | 20% | N/A | N/A |
What Is BioMotiv?
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million US and UK initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$166.8M
Total Funding
7
Number of Employees
$542.5k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
BioMotiv News
... commercial entities, Advent-Harrington Impact Fund and BioMotiv, and to its charitable partner Morgan Stanley GIFT Cures.
CLEVELAND & NEW YORK--(BUSINESS WIRE)--BioMotiv, a mission-driven drug development accelerator that advances breakthrough ...
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis ...
Bristol-Myers Squibb has allied with biotech accelerator BioMotiv. The deal sets Bristol-Myers up to found and fund biotechs with BioMotiv ...
BioMotiv is the for-profit affiliate of University Hospitals’ Harrington Project, a $250 million initiative created to bridge the “valley of death” in drug development by accelerating the development and commercialization of medical breakthroughs from research centers. Calls to Sujana Biotech a ...
Other Companies in Cleveland
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.5M | 7 | 0% | N/A |
#2 | $0.5M | 7 | 0% | N/A |
#3 | $0.5M | 7 | 0% | N/A |
#4 | $0.5M | 7 | -36% | N/A |
#5 | $0.5M | 7 | 0% | N/A |
BioMotiv Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2012-09-06 | $21.0M | Undisclosed | University Hospitals, Harrington Family | Article |
| 2013-08-06 | $46.0M | Undisclosed | Nationwide Mutual Insurance Co | Article |
| 2014-08-15 | $51.0M | Undisclosed | Article | |
| 2014-09-29 | $25.0M | Undisclosed | Takeda Pharmaceutical Company Limited | Article |
| 2016-04-15 | $10.0M | Undisclosed | Charles River Laboratories International Inc | Article |
| 2016-08-09 | $63.0M | Undisclosed | Article |